mAbxience enters into an agreement with AstraZeneca to produce Covid-19 vaccine

Monday, August 17, 2020

mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America.

Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico to complete the production and filling process.

The agreement with AstraZeneca, and financed mainly by the Carlos Slim Foundation,will provide more than 200 million doses of the vaccine to be supplied to all Latin American countries, except Brazil.

AstraZeneca is one of the largest drug manufacturers in the world, and in partnership with the University of Oxford, has achieved highly promising results with this vaccine. Being selected as a partner for such a crucial project clearly evidences that mAbxience is a top-level, trusted partner with extremely solid quality standards.

Activities to transfer AstraZeneca technology to the Garín plant will begin shortly, so the facilities at our new plant will be fully dedicated to the production of vaccines over the coming months. Meanwhile, our plants in Munro in Argentina and León in Spain will continue working hard at maximum capacity, guaranteeing the supply of our biosimilars and the fulfilment of our commitments.

The Covid 19 vaccine AZD1222 showed robust immune responses in all participants in phase 1 and 2 trial, as reported by The Lancet. The phase 3 trial is currently ongoing and scheduled to be completed in the coming months. The vaccine is expected to be delivered in the first half of 2021, upon completion of the phase 3 trial and regulatory approvals.

We are very proud to be a direct part of the global efforts underway to defeat this pandemic, which is impacting the lives of millions of people around the world.